Cytodyn Inc (CYDY)

[stockorus]

It wasn't a random selection -- it didn't have a matched panel, it wasn't a quota sample that would be required to be a viable subsample. It was a post-hoc, data dredged sample.

It was random within the constraints of the protocol and the parameters by which that subgroup is identified. Out of the ~394 patients who fit the general criteria and were enrolled following the rules of double blinded trials, 62 happened to be fitting the specific critical criteria, don't recall but perhaps requiring ecmo. The patients were not preselected specially. From this group, we were able to narrow down the optimal criteria for our next trial.